Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05698199
Title Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Immunomic Therapeutics, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.